ADtouch: Lebrikizumab Eases Itch and Pain in Hand and Foot Eczema
Eli Lilly's lebrikizumab (Ebglyss) showed significant improvement in skin clearance, itch, and pain for hand and foot eczema in a phase 3b trial, with 53% of patients achieving clear or almost clear skin at 16 weeks vs 27% on placebo. The trial also reported rapid itch relief and high patient satisfaction. Safety was consistent with known profiles. Presented at EADV Congress 2026.
How this was made
The 30-second read
Why it matters
The data provide a new indication, expanding the drug's market potential and may drive near-term stock movement.
Market read
First-time positive Phase 3b data for a new dermatology indication could catalyze stock upside.
What to watch
Potential competition from other IL-13 inhibitors and payer reimbursement uncertainties.
Background
Eli Lilly's lebrikizumab (EBGLYSS) is an IL-13 inhibitor previously approved for asthma; the ADtouch trial explores its use in hand and foot atopic dermatitis.
Ticker impact
Phase 3b ADtouch trial data for lebrikizumab (EBGLYSS) were presented for the first time, showing 53% clear/almost clear response versus 27% placebo.
likely upward pressure as market prices in potential label expansion
First disclosure of statistically significant efficacy in a new indication; biotech stocks typically react positively to such data.
Market effects
strengthens outlook for atopic dermatitis therapeutics and may boost peer biotech valuations
U.S. biotech sector
moderate, limited to healthcare investors
Counterpoint
If the trial data do not translate into regulatory approval or commercial uptake, the rally could be short-lived.
Key entities
- CompanyEli Lilly and Company
Pharmaceutical developer of lebrikizumab.
- PersonDr. Shawn G. Kwatra
Dermatology professor discussing trial results.
